Previous 10 | Next 10 |
Nyxoah Appoints Dr. Maurits S. Boon, MD as Chief Medical Officer Mont-Saint-Guibert, Belgium – April 11, 2024, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused...
2024-04-11 10:04:28 ET More on Health Care Select Sector SPDR XLV: Fundamentals Don't Support Overweighting Health Care XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run Well...
Nyxoah Advances Patient Access Strategy through Partnership with the American Association of Otolaryngology – Head & Neck Surgery Foundation First medical device company to become a corporate champion at the ENTerprise Circle level Mont-Saint-Guibert, Belgium – Mar...
2024-03-19 17:51:36 ET More on Nyxoah Nyxoah S.A. (NYXH) Q4 2023 Earnings Call Transcript Nyxoah expects to almost double revenue in 4Q23 Seeking Alpha’s Quant Rating on Nyxoah Historical earnings data for Nyxoah Financial information for Nyxoa...
Nyxoah Announces DREAM U.S. Pivotal Study Meets Primary Endpoints Reports an Apnea-Hypopnea Index (AHI) responder rate of 63.5% on an intent to treat (ITT) basis (p=0.002) Reports an Oxygen Desaturation Index (ODI) responder rate of 71.3% on an intent to treat (ITT) basis (p<0.00...
2024-03-18 05:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-03-05 18:49:04 ET Nyxoah S.A. (NYXH) Q4 2023 Earnings Conference Call March 5, 2024, 4:30 pm ET Company Participants Mikaela Kirkwood - Corporate Communications & IR Manager Olivier Taelman - CEO Loïc Moreau - CFO Conference Call Participants ...
2024-03-05 16:17:54 ET More on Nyxoah Nyxoah expects to almost double revenue in 4Q23 Seeking Alpha’s Quant Rating on Nyxoah Historical earnings data for Nyxoah Financial information for Nyxoah Read the full article on Seeking Alpha For...
Nyxoah Reports Fourth Quarter and Financial Year 2023 Financial and Operating Results Expect to report DREAM U.S. pivotal study efficacy and safety data by early April Achieved record quarterly sales of €1.8 million Mont-Saint-Guibert, Belgium – March 5, 2024 10:...
Carisma Therapeutics Inc. (CARM) is expected to report $-0.56 for Q4 2023 First Acceptance Corp. (FACO) is expected to report for quarter end 2023-12-31 Bell Copper Corp (BCUFF) is expected to report for quarter end 2023-12-31 BioHarvest Sciences Inc (CNVCF) is expected to report for ...
News, Short Squeeze, Breakout and More Instantly...
Nyxoah Appoints Scott Holstine as Chief Commercial Officer Mont-Saint-Guibert, Belgium – July 15, 2024, 8:00am CET / 2:00am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the ...
REGULATED INFORMATION INSIDE INFORMATION Nyxoah Has Signed a €37.5 Million Loan Facility Agreement with the European Investment Bank Mont-Saint-Guibert, Belgium – July 3, 2024, 12:30pm CET / 6:30am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (&...
Nyxoah Submits Fourth and Final Module in PMA Application for Genio to the US FDA Mont-Saint-Guibert (Belgium), July 1, 2024 , 8:00am CET / 2:00am ET – (“Nyxoah” or the “Company”), a medical technology company focused on the develop...